[FG] Wild Damian

Santini, Francesco et al. (2024) ‘ESR Essentials: advanced MR safety in vulnerable patients—practice recommendations by the European Society for Magnetic Resonance in Medicine and Biology’, European Radiology [Preprint]. Available at: https://doi.org/10.1007/s00330-024-11055-1.

Barzaghi, Leonardo et al. (2024) ‘Muscle diffusion tensor imaging in facioscapulohumeral muscular dystrophy’, Muscle & Nerve, 70(2), pp. 248–256. Available at: https://doi.org/10.1002/mus.28179.

Barzaghi, Leonardo et al. (2024) ‘Myo-regressor Deep Informed Neural NetwOrk (Myo-DINO) for fast MR parameters mapping in neuromuscular disorders’, Computer Methods and Programs in Biomedicine [Preprint]. Available at: https://doi.org/https://doi.org/10.1016/j.cmpb.2024.108399.

Beck, Julia et al. (2024) ‘Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms’, Endocrine-Related Cancer, 31. Available at: https://doi.org/10.1530/erc-23-0235.

Fricke, Julia et al. (2024) ‘First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([ 161 Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum’, European Journal of Nuclear Medicine and Molecular Imaging [Preprint]. Available at: https://doi.org/10.1007/s00259-024-06641-w.

Rottenburger, Christof et al. (2024) ‘In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [ 177 Lu]Lu-PP-F11N in humans: the lumed phase 0b study’, EJNMMI Research, 14. Available at: https://doi.org/10.1186/s13550-024-01101-w.

Rottenburger, Christof et al. (2024) ‘Results of the phase I “Lumed ” study: Dose escalation of 177Lu-PP-F11N in patients with medullary thyroid carcinoma.’, in Annual Congress of the European Association of Nuclear Medicine . Hamburg, Deutschland (Annual Congress of the European Association of Nuclear Medicine ).

Schürrle, Seval Beykan et al. (2024) ‘Dosimetry and pharmacokinetics of [ 177 Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours’, European Journal of Nuclear Medicine and Molecular Imaging [Preprint]. Available at: https://doi.org/10.1007/s00259-024-06682-1.

von Niederhäusern, P.A. et al. (2024) ‘Augmented reality for sentinel lymph node biopsy’, International Journal of Computer Assisted Radiology and Surgery, 19, pp. 171–180. Available at: https://doi.org/10.1007/s11548-023-03014-w.

Askari E et al. (2023) ‘Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review.’, Journal of nuclear medicine technology, 51(1), pp. 22–25. Available at: https://doi.org/10.2967/jnmt.122.264904.

Kudura K et al. (2023) ‘Additional Primary Tumors Detected Incidentally on FDG PET/CT at Staging in Patients with First Diagnosis of NSCLC: Frequency, Impact on Patient Management and Survival.’, Cancers, 15(5). Available at: https://doi.org/10.3390/cancers15051521.

Fani, Melpomeni and Nicolas, Guillaume P. (2023) ‘⁶¹Cu-labeled radiotracers: Alternative or choice?’, Journal of Nuclear Medicine, 64, pp. 1855–1857. Available at: https://doi.org/10.2967/jnumed.123.266171.

Hemmig, Andrea K. et al. (2023) ‘Magnetic Resonance Imaging Findings Corresponding to Vasculitis as Defined via [¹⁸F]FDG Positron Emission Tomography or Ultrasound’, Diagnostics, 13. Available at: https://doi.org/10.3390/diagnostics13233559.

Imperiale, Alessio et al. (2023) ‘The Emergence of Somatostatin Antagonist–Based Theranostics: Paving the Road Toward Another Success?’, Journal of Nuclear Medicine, 64, pp. 682–684. Available at: https://doi.org/10.2967/jnumed.123.265406.

Karnam, Murali et al. (2023) ‘Qualitative and quantitative assessment of admittance controllers for hand-guiding surgical robots’, At-Automatisierungstechnik, 71, pp. 515–527. Available at: https://doi.org/10.1515/auto-2023-0063.

Mallaev, Makhmudbek et al. (2023) ‘3D-Quantitated Single Photon Emission Computed Tomography/Computed Tomography: Impact on intended Management Compared to Lung Perfusion Scan in Marginal Candidates for Pulmonary Resection’, Clinical Lung Cancer, 24(7), pp. 621–630. Available at: https://doi.org/10.1016/j.cllc.2023.07.006.

Maushart, Claudia Irene et al. (2023) ‘Effect of high-dose glucocorticoid treatment on human brown adipose tissue activity: a randomised, double-blinded, placebo-controlled cross-over trial in healthy men’, eBioMedicine, 96. Available at: https://doi.org/10.1016/j.ebiom.2023.104771.

Schmidlin, Moira et al. (2023) ‘Improvement of Lung NET Management through Standardized Care—A Swiss Nationwide Observational Study’, Cancers, 15. Available at: https://doi.org/10.3390/cancers15082270.

Sira, Lívia et al. (2023) ‘Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies’, Frontiers in Endocrinology, 14. Available at: https://doi.org/10.3389/fendo.2023.1095815.

Wild, Damian et al. (2023) ‘A phase I/II study of the safety and efficacy of [ 177 Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours’, European Journal of Nuclear Medicine and Molecular Imaging, 51, pp. 183–195. Available at: https://doi.org/10.1007/s00259-023-06383-1.

Kudura K et al. (2022) ‘Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors.’, Cancers, 14(24). Available at: https://doi.org/10.3390/cancers14246095.

Antwi K et al. (2022) ‘Hypermetabolic Ipsilateral Supraclavicular and Axillary Lymphadenopathy: Optimal Time Point for Performing an (18)F-FDG PET/CT after COVID-19 Vaccination.’, Diagnostics (Basel, Switzerland), 12(12). Available at: https://doi.org/10.3390/diagnostics12123073.

Varum F et al. (2022) ‘Targeted colonic release formulations of mesalazine - A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis.’, International journal of pharmaceutics, 625, p. 122055. Available at: https://doi.org/10.1016/j.ijpharm.2022.122055.

Hasegawa S. et al. (2022) ‘Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors’, Cancers, 14(14). Available at: https://doi.org/10.3390/cancers14143317.

Refardt J et al. (2022) ‘Molecular Imaging of Neuroendocrine Neoplasms’, Journal of Clinical Endocrinology and Metabolism, 107(7), pp. E2662–E2670. Available at: https://doi.org/10.1210/clinem/dgac207.

Christ E, Wild D and Refardt J (2022) ‘Molecular Imaging in neuroendocrine neoplasias.’, Presse medicale (Paris, France : 1983), 51(2), p. 104115. Available at: https://doi.org/10.1016/j.lpm.2022.104115.

Freitag MT et al. (2022) ‘Quantitative myocardial perfusion (82)Rb-PET assessed by hybrid PET/coronary-CT: Normal values and diagnostic performance.’, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 29(2), pp. 464–473. Available at: https://doi.org/10.1007/s12350-020-02264-4.

Imfeld S et al. (2022) ‘A Simplified PET/CT Measurement Routine with Excellent Diagnostic Accuracy for the Diagnosis of Giant Cell Arteritis.’, Diagnostics (Basel, Switzerland), 12(3). Available at: https://doi.org/10.3390/diagnostics12030728.

Hicks RJ et al. (2022) ‘ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours.’, Journal of neuroendocrinology, 34(3), p. e13040. Available at: https://doi.org/10.1111/jne.13040.

Prasad V et al. (2022) ‘Reply: (68)Ga NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 63(3), pp. 493–494. Available at: https://doi.org/10.2967/jnumed.121.263167.

Boss M et al. (2022) ‘(68)Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 63(2), pp. 310–315. Available at: https://doi.org/10.2967/jnumed.121.262327.

Theiler D. et al. (2021) ‘Safety and efficacy of peptide-receptor radionuclide therapy in elderly neuroendocrine tumor patients’, Cancers, 13(24). Available at: https://doi.org/10.3390/cancers13246290.

Hayes AR et al. (2021) ‘Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy.’, The Journal of clinical endocrinology and metabolism, 106(12), pp. e4903–e4916. Available at: https://doi.org/10.1210/clinem/dgab588.

von Guggenberg E et al. (2021) ‘Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals.’, Cancers, 13(22). Available at: https://doi.org/10.3390/cancers13225776.

Refardt J et al. (2021) ‘New Directions in Imaging Neuroendocrine Neoplasms.’, Current oncology reports, 23(12), p. 143. Available at: https://doi.org/10.1007/s11912-021-01139-2.

Kobayashi N et al. (2021) ‘Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors.’, Journal of hepato-biliary-pancreatic sciences, 28(9), pp. 727–739. Available at: https://doi.org/10.1002/jhbp.1014.

Refardt J et al. (2021) ‘Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.’, Reviews in endocrine & metabolic disorders, 22(3), pp. 581–594. Available at: https://doi.org/10.1007/s11154-020-09552-x.

Wild D et al. (2021) ‘Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 62(Suppl 2), pp. 44S–50S. Available at: https://doi.org/10.2967/jnumed.120.246009.

Mansi R and Fani M (2021) ‘Radiolabeled Peptides for Cancer Imaging and Therapy: From Bench-to-Bedside.’, Chimia, 75(6), pp. 500–504. Available at: https://doi.org/10.2533/chimia.2021.500.

Braun M et al. (2021) ‘Accuracy comparison of various quantitative [(99m)Tc]Tc-DPD SPECT/CT reconstruction techniques in patients with symptomatic hip and knee joint prostheses.’, EJNMMI research, 11(1), p. 60. Available at: https://doi.org/10.1186/s13550-021-00794-7.

Gaonkar RH et al. (2021) ‘SPECT Imaging of SST2-Expressing Tumors with (99m)Tc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers.’, Pharmaceuticals (Basel, Switzerland), 14(4). Available at: https://doi.org/10.3390/ph14040300.

Ambrosini V et al. (2021) ‘Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.’, European journal of cancer (Oxford, England : 1990), 146, pp. 56–73. Available at: https://doi.org/10.1016/j.ejca.2021.01.008.

Antwi K et al. (2021) ‘Investigating difficult to detect pancreatic lesions: Characterization of benign pancreatic islet cell tumors using multiparametric pancreatic 3-T MRI.’, PloS one, 16(6), p. e0253078. Available at: https://doi.org/10.1371/journal.pone.0253078.

Hess, Gabriel Fridolin et al. (2021) ‘Surgical Strategy Based on Radiological 3D Reconstruction in a Giant Metastatic Neuroendocrine Tumor of the Pancreas: A Case Report of an Interdisciplinary Approach’, Case Reports in Surgery, 2021(8811155). Available at: https://doi.org/10.1155/2021/8811155.

Preisig, Daniel et al. (2021) ‘Colonic delivery of metronidazole-loaded capsules for local treatment of bacterial infections: a clinical pharmacoscintigraphy study’, European Journal of Pharmaceutics and Biopharmaceutics, 165, pp. 22–30. Available at: https://doi.org/10.1016/j.ejpb.2021.05.002.

Rottenburger, Christof et al. (2021) ‘¹⁸F-FDG PET/CT compared with ultrasound and biopsy for detection of vasculitis of the temporal artery branches’, Swiss Medical Weekly, 151. Available at: https://doi.org/10.4414/smw.2021.20512.

Fani M et al. (2020) ‘Selection of the First (99m)Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation-Preclinical Assessment of Two Optimized Candidates.’, Pharmaceuticals (Basel, Switzerland), 14(1). Available at: https://doi.org/10.3390/ph14010019.

Schaerli N et al. (2020) ‘Incremental value of high-frequency QRS analysis for diagnosis and prognosis in suspected exercise-induced myocardial ischaemia.’, European heart journal. Acute cardiovascular care, 9(8), pp. 836–847. Available at: https://doi.org/10.1177/2048872619842988.

Rottenburger C and Lutz T (2020) ‘[The ablative radioiodine therapy of differentiated thyroid carcinoma].’, Therapeutische Umschau. Revue therapeutique, 77(9), pp. 427–431. Available at: https://doi.org/10.1024/0040-5930/a001214.

Caobelli F et al. (2020) ‘Quantitative (99m)Tc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores.’, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 27(5), pp. 1456–1463. Available at: https://doi.org/10.1007/s12350-019-01893-8.

Mansi R et al. (2020) ‘Evaluation of a New (177)Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5.’, Molecules (Basel, Switzerland), 25(18). Available at: https://doi.org/10.3390/molecules25184155.

Antwi K et al. (2020) ‘Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging.’, Clinical nuclear medicine, 45(9), pp. e386–e392. Available at: https://doi.org/10.1097/rlu.0000000000003124.

Häfliger S et al. (2020) ‘Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor.’, 13(3). Available at: https://doi.org/10.1159/000510334.

Mansi R et al. (2020) ‘A new (68)Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting.’, EJNMMI research, 10(1), p. 90. Available at: https://doi.org/10.1186/s13550-020-00677-3.

Fischer JGW et al. (2020) ‘Comparison of [(18)F]FDG PET/CT with magnetic resonance imaging for the assessment of human brown adipose tissue activity.’, EJNMMI research, 10(1), p. 85. Available at: https://doi.org/10.1186/s13550-020-00665-7.

Schunemann M.J. et al. (2020) ‘Wither Away: Weight Loss and Persistent Inflammation in a Woman With Whipple Disease’, American Journal of Medicine, 133(6), pp. e223–e226. Available at: https://doi.org/10.1016/j.amjmed.2019.08.058.

Christ E et al. (2020) ‘Innovative imaging of insulinoma: the end of sampling? A review.’, Endocrine-related cancer, 27(4), pp. R79–R92. Available at: https://doi.org/10.1530/erc-19-0476.

Imfeld S et al. (2020) ‘[18F]FDG positron emission tomography and ultrasound in the diagnosis of giant cell arteritis: congruent or complementary imaging methods?’, Rheumatology (Oxford, England), 59(4), pp. 772–778. Available at: https://doi.org/10.1093/rheumatology/kez362.

Rottenburger C et al. (2020) ‘Cholecystokinin 2 Receptor Agonist (177)Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 61(4), pp. 520–526. Available at: https://doi.org/10.2967/jnumed.119.233031.

Maas O et al. (2020) ‘Variations in radioiodine ablation: decision-making after total thyroidectomy.’, European journal of nuclear medicine and molecular imaging, 47(3), pp. 554–560. Available at: https://doi.org/10.1007/s00259-019-04557-4.

Coto-Llerena, Mairene et al. (2020) ‘High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes’, Frontiers in Oncology, 10, p. 979. Available at: https://doi.org/10.3389/fonc.2020.00979.

Hepprich M et al. (2020) ‘Brunner’s Gland Hyperplasia in a Patient after Roux-Y Gastric Bypass: An Important Pitfall in GLP-1 Receptor Imaging.’, 2020. Available at: https://doi.org/10.1155/2020/4510910.

Antwi K et al. (2019) ‘68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1.’, The Journal of clinical endocrinology and metabolism, 104(12), pp. 5843–5852. Available at: https://doi.org/10.1210/jc.2018-02754.

von Niederhäusern PA et al. (2019) ‘Augmenting camera images with gamma detector data: A novel approach to support sentinel lymph node biopsy’, EJNMMI Physics, 6(1), p. 10. Available at: https://doi.org/10.1186/s40658-019-0245-z.

Zamboglou C et al. (2019) ‘Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference.’, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 141, pp. 208–213. Available at: https://doi.org/10.1016/j.radonc.2019.07.002.

Mansi R. and Fani M. (2019) ‘Design and development of the theranostic pair 177Lu-OPS201/68Ga-OPS202 for targeting somatostatin receptor expressing tumors’, Journal of Labelled Compounds and Radiopharmaceuticals, 62(10), pp. 635–645. Available at: https://doi.org/10.1002/jlcr.3755.

Buitinga M et al. (2019) ‘Succinylated gelatin improves the theranostic potential of radiolabeled exendin-4 in insulinoma patients’, Journal of Nuclear Medicine. 30.11.2018, 60(6), pp. 812–816. Available at: https://doi.org/10.2967/jnumed.118.219980.

Wolf KI et al. (2019) ‘Eruption of Metastatic Paraganglioma After Successful Therapy with (177)Lu/(90)Y-DOTATOC and (177)Lu-DOTATATE.’, 53(3). Available at: https://doi.org/10.1007/s13139-019-00579-w.

Antwi K et al. (2019) ‘Volume Replacement Fluid Demarks Benign Insulinoma With 68Ga-DOTA-Exendin-4 PET/CT.’, Clinical nuclear medicine, 44(5), pp. e347–e348. Available at: https://doi.org/10.1097/rlu.0000000000002522.

Aschwanden M et al. (2019) ‘Vessel wall plasticity in large vessel giant cell arteritis: An ultrasound follow-up study’, Rheumatology (United Kingdom), 58(5), pp. 792–797. Available at: https://doi.org/10.1093/rheumatology/key383.

Antwi K et al. (2019) ‘Molecular imaging for neuroendocrine tumours.’, Swiss medical weekly, 149, p. w20017. Available at: https://doi.org/10.4414/smw.2019.20017.

Beykan S et al. (2019) ‘In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry.’, Contrast media & molecular imaging, 2019, p. 6438196. Available at: https://doi.org/10.1155/2019/6438196.

Dastamani A et al. (2019) ‘The Use of a Long-Acting Somatostatin Analogue (Lanreotide) in Three Children with Focal Forms of Congenital Hyperinsulinaemic Hypoglycaemia.’, 91(1). Available at: https://doi.org/10.1159/000491101.

Honegger, Ursina et al. (2019) ‘Prevalence and determinants of exercise-induced left ventricular dysfunction in patients with coronary artery disease’, European journal of clinical investigation, 49(6), p. e13112. Available at: https://doi.org/10.1111/eci.13112.

Sauter AW et al. (2019) ‘Targeting of the cholecystokinin-2 receptor with the minigastrin analog 177 Lu-DOTA-PP-F11N: Does the use of protease inhibitors further improve in vivo distribution?’, Journal of Nuclear Medicine. 12.07.2018, 60(3), pp. 393–399. Available at: https://doi.org/10.2967/jnumed.118.207845.

von Niederhausern P.A. et al. (2019) ‘Gamma Source Location Learning from Synthetic Multi-pinhole Collimator Data’. Springer Science and Business Media Deutschland GmbH, pp. 205–214. Available at: https://doi.org/10.1007/978-3-030-33843-5_19.

Nicolas GP et al. (2018) ‘New Developments in Peptide Receptor Radionuclide Therapy.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine [Preprint]. Available at: https://doi.org/10.2967/jnumed.118.213496.

Antwi K et al. (2018) ‘Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.’, European journal of nuclear medicine and molecular imaging, 45(13), pp. 2318–2327. Available at: https://doi.org/10.1007/s00259-018-4101-5.

Valente LG et al. (2018) ‘Clinical presentation of 54 patients with endogenous hyperinsulinaemic hypoglycaemia: a neurological chameleon (observational study).’, Swiss medical weekly, 148, p. w14682. Available at: https://doi.org/10.4414/smw.2018.14682.

Omlin, Aurelius et al. (2018) ‘[Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation].’, Praxis, 107(19), pp. 1043–1051. Available at: https://doi.org/10.1024/1661-8157/a003054.

Berger CT et al. (2018) ‘The clinical benefit of imaging in the diagnosis and treatment of giant cell arteritis.’, Swiss medical weekly, 148, p. w14661. Available at: https://doi.org/10.4414/smw.2018.14661.

Nicolas GP et al. (2018) ‘Safety, Biodistribution, and Radiation Dosimetry of (68)Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 59(6), pp. 909–914. Available at: https://doi.org/10.2967/jnumed.117.199737.

Nicolas GP et al. (2018) ‘Sensitivity Comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 59(6), pp. 915–921. Available at: https://doi.org/10.2967/jnumed.117.199760.

Nock B.A. et al. (2018) ‘New Gastrin Releasing Peptide Receptor-Directed [ 99m Tc]Demobesin 1 Mimics: Synthesis and Comparative Evaluation’, Journal of Medicinal Chemistry, 61(7), pp. 3138–3150. Available at: https://doi.org/10.1021/acs.jmedchem.8b00177.

Rottenburger C et al. (2018) ‘A Case Series of Molecular Imaging of Glucagonoma After Initial Therapy-68Ga-DOTATATE PET/CT Reveals Similar Results as in Neuroendocrine Tumors of Other Origin in Follow-up and Re-evaluation.’, Clinical nuclear medicine, 43(4), pp. 252–255. Available at: https://doi.org/10.1097/rlu.0000000000002005.

Nicolas GP, Wild D and Fani M (2018) ‘Reply: Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists.’, 59(3). Available at: https://doi.org/10.2967/jnumed.117.203703.

Abiraj, Keelara et al. (2018) ‘The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist’, EJNMMI research, 8, p. 75. Available at: https://doi.org/10.1186/s13550-018-0428-y.

Badertscher, Patrick et al. (2018) ‘Automatically computed ECG algorithm for the quantification of myocardial scar and the prediction of mortality’, Clinical research in cardiology, 107(9), pp. 824–835. Available at: https://doi.org/10.1007/s00392-018-1253-z.

Müller, Deborah et al. (2018) ‘Direct Comparison of Cardiac Troponin T and I Using a Uniform and a Sex-Specific Approach in the Detection of Functionally Relevant Coronary Artery Disease’, Clinical chemistry, 64(11), pp. 1596–1606. Available at: https://doi.org/10.1373/clinchem.2018.286971.

Puelacher, Christian et al. (2018) ‘Combining high-sensitivity cardiac troponin and B-type natriuretic peptide in the detection of inducible myocardial ischemia’, Clinical biochemistry, 52, pp. 33–40. Available at: https://doi.org/10.1016/j.clinbiochem.2017.10.014.

Rylova SN et al. (2018) ‘The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.’, PloS one. 18.04.2018, 13(4), p. e0195802. Available at: https://doi.org/10.1371/journal.pone.0195802.

Walter, Joan E. et al. (2018) ‘Prospective Validation of a Biomarker-Based Rule Out Strategy for Functionally Relevant Coronary Artery Disease’, Clinical chemistry, 64(2), pp. 386–395. Available at: https://doi.org/10.1373/clinchem.2017.277210.

Katona B.W. et al. (2017) ‘Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective Analysis’, Pancreas, 46(9), pp. 1121–1126. Available at: https://doi.org/10.1097/mpa.0000000000000919.

Fani M, Nicolas GP and Wild D (2017) ‘Somatostatin Receptor Antagonists for Imaging and Therapy.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 58(Suppl 2), pp. 61S–66S. Available at: https://doi.org/10.2967/jnumed.116.186783.

Magaton IM et al. (2017) ‘Spontaneous Remission of Severe Systemic Langerhans Cell Histiocytosis with Bladder Involvement: A Case Study.’, 10(3). Available at: https://doi.org/10.1159/000480696.

Nicolas GP et al. (2017) ‘Biodistribution, Pharmacokinetics, and Dosimetry of (177)Lu-, (90)Y-, and (111)In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist (177)Lu-DOTATATE: The Mass Effect.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 58(9), pp. 1435–1441. Available at: https://doi.org/10.2967/jnumed.117.191684.

Puelacher C et al. (2017) ‘Diagnostic value of ST-segment deviations during cardiac exercise stress testing: Systematic comparison of different ECG leads and time-points.’, International journal of cardiology, 238, pp. 166–172. Available at: https://doi.org/10.1016/j.ijcard.2017.02.079.

Wan MYS et al. (2017) ‘PET/CT Imaging of Unstable Carotid Plaque with (68)Ga-Labeled Somatostatin Receptor Ligand.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 08.12.2016, 58(5), pp. 774–780. Available at: https://doi.org/10.2967/jnumed.116.181438.

Wagener M et al. (2017) ‘Diagnostic and Prognostic Value of Lead aVR During Exercise Testing in Patients Suspected of Having Myocardial Ischemia.’, The American journal of cardiology, 119(7), pp. 959–966. Available at: https://doi.org/10.1016/j.amjcard.2016.11.056.

Fani M, Peitl PK and Velikyan I (2017) ‘Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.’, Pharmaceuticals (Basel, Switzerland), 10(1). Available at: https://doi.org/10.3390/ph10010030.